Pfizer (PFE), Valneva (VALN) Lyme Vaccine Moves to EMA Review Despite Phase 3 Caveat

Reported by Yahoo Finance · Published 16 Sep 2026, 12:21 AM MYT (6 hr ago)

Summary

Source & full coverage: this summary is aggregated from Yahoo Finance, the original publisher. Read the complete report for full context, data and quotes.

Read the original report at Yahoo Finance →

Most Recent

OpenAI mulls funding round at $1.2 trillion valuation ahead of IPO, FT reports 24 min ago Meta plans to launch camera-free smart glasses for fall, The Information reports 28 min ago Nvidia boss says AI 'doesn't need new laws' as safety concerns grow 51 min ago OpenAI backs bills in US Congress on AI and biological weapon threats 57 min ago There were many conductors in the derailment of the crypto industry's Clarity Act 1 hr ago Gucci owner Kering is backing Chinese fashion brand Icicle. Can it become a global luxury name? 1 hr ago

EconPulse

Markets. Economy. Malaysia & The World.

Independent economic news aggregation for Malaysia, Asia and global markets, updated throughout the day.

Company

About Us Editorial Standards & Corrections Privacy Policy

Work With Us

Submit a Press Release Partnerships & Advertising Contact Us RSS Feed

Contact

editor@econpulse.my

Editorial & newsroom enquiries answered within 1–2 business days.

Pfizer (PFE), Valneva (VALN) Lyme Vaccine Moves to EMA Review Despite Phase 3 Caveat

Summary

More in Markets

These 4 stocks could benefit most from a $3.2 trillion semiconductor opportunity

Inflation killed the penny. Now it’s coming for your dollar.

2 charts showing how oil is becoming the global market’s biggest wild card

Why a Federal Reserve rate hike could be a ‘rare win’ for your retirement money

Top Senate Republican floats a diesel export ban as prices soar. It might not work.

Oracle’s stock falls for the fifth day in a row — missing out on the AI bounce